Company intelligence / Profile preview
Aspire Health Science
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 2
Overview
Aspire Health Science specializes in contract manufacturing and development of advanced cellular therapies under cGMP guidelines. Its lead clinical program (ACT-20) has reached Phase1/2 trials for COVID-19 pneumonia. The company provides regulatory, analytical, and manufacturing services to support the development of cell and gene therapies.
- Therapeutic areas
- PulmonologyCardiovascularInfectious Diseases
- Modalities
- Cellular therapiesMesenchymal stem cell therapyStem cell therapy
- Industry
- Contract Manufacturing Organization
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Aspire Health Science.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aspire Health Science.